Eli Lilly and Company, with US Food and Drug Administration approval on 2 July for Kisunla (donanemab-azbt) for early Alzheimer’s disease, is set to give Eisai Co., Ltd. and Biogen, Inc. a run for their money a year after the partners won full approval of their anti-amyloid antibody Leqembi (lecanemab). Kisunla is dosed less frequently and has a potential cost advantage that may help Lilly rapidly build on the groundwork that Eisai has laid with Leqembi.
Key Takeaways
-
The US FDA approved Lilly’s Kisunla (donanemab) for early Alzheimer’s disease, with labeling that allows doctors to end treatment when patients achieve negative amyloid on PET scans.
The list price for Kisunla works out to $32,000 for a year of treatment, which is nearly 21% higher than...
